Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fulminant hepatic failure.

David A Sass1, A Obaid Shakil

  • 1Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, PUH, Mezzanine Level, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

Gastroenterology Clinics of North America
|December 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Rare Case of Fluid Overload-Associated Large B-Cell Lymphoma in a Patient With Hepatitis C Cirrhosis.

ACG case reports journal·2026
Same author

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment.

BMC gastroenterology·2024
Same author

Striking Cholestatic Giant Cell Hepatitis Resulting in Fulminant Liver Failure After Garcinia Cambogia Use.

International journal of surgical pathology·2023
Same author

Hepatitis B in Heart Transplant Donors and Recipients: A Systematic Review and Meta-Analysis.

The Journal of surgical research·2023
Same author

Acute Liver Failure Requiring Liver Transplantation due to Acute Hepatitis A Virus Infection.

Case reports in transplantation·2022
Same author

Duodenal Perforation With Transplant Hepatic Artery Pseudoaneurysm.

ACG case reports journal·2019
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Fulminant hepatic failure (FHF) requires prompt management and liver transplantation. Liver support devices offer hope for improving outcomes by bridging patients to transplant or regeneration.

Area of Science:

  • Hepatology
  • Transplantation Medicine
  • Biomedical Engineering

Background:

  • Fulminant hepatic failure (FHF) is a severe condition with high mortality, affecting individuals with previously healthy livers.
  • Hepatic encephalopathy is the hallmark clinical manifestation of FHF, necessitating urgent and specialized care.
  • The critical shortage of donor livers presents a significant challenge in managing FHF patients.

Purpose of the Study:

  • To review the current landscape of managing fulminant hepatic failure (FHF).
  • To explore the role and limitations of liver support devices in FHF management.
  • To discuss future directions in FHF treatment, including technological advancements and regenerative strategies.

Main Methods:

  • Review of current clinical practices for FHF management, emphasizing multidisciplinary approaches.

Related Experiment Videos

  • Analysis of the potential and challenges of existing and emerging liver support systems.
  • Discussion of advancements in hepatocyte transplantation, xenografting, and liver regeneration.

    • Main Results:

    • Effective liver support devices can extend the time window for liver transplantation or native liver regeneration.
    • Hybrid liver support systems show promise but have not yet achieved ideal synthetic function.
    • Controlled trials are crucial for validating the clinical utility of liver support devices.

    Conclusions:

    • Advancements in hybrid systems, hepatocyte transplantation, and xenografting may offer new therapeutic avenues for FHF.
    • Enhanced understanding of liver cell death and regeneration mechanisms is vital for targeted therapies.
    • Multicenter trials are essential to establish the efficacy of novel FHF management strategies.